Press Releases

15 April 2024 15:30Ziccum AB (publ) publicerar Årsredovisning 202NewsSwedishRegulatoryListing RegulationReportAnnualIR
Ziccum AB meddelar idag att bolagets årsredovisning för 2023 nu finns tillgänglig på bolagets hemsida www.ziccum.com. För att läsa hela rapporten, på svenska, vänligen besök: https://ziccum.com/investors/financial-reports/...
15 April 2024 15:30Ziccum AB (publ) releases Annual Report 2023NewsEnglishRegulatoryListing RegulationReportAnnualIR
Ziccum today announces that its Annual Report for 2023 is now available on the company’s website www.ziccum.com. To read the Report in full (in Swedish) please visit here: https://ziccum.com/investors/financial-reports/ For more information about...
10 April 2024 14:20Ziccum CEO to present at first annual event for Biopharma/Biotech disruptors hosted by major US bank in New York CityNewsCorporate InformationOther Corporate InformationEnglishIR
On Tuesday May 14th, in Park Avenue New York City, Ziccum CEO Ann Gidner will present at the first event on high-value biotech and biopharma disruptor technologies to be hosted by CapitalOne, one of the US’ largest bank corporations. She will present...
3 April 2024 16:32Ziccum strengthens and streamlines business and finance functionsNewsCorporate InformationOther Corporate InformationEnglishRegulatoryListing RegulationIR
Ziccum is reorganizing its administrative functions, due to the increased amount of business dialogues and to perform financial reporting in a more streamlined fashion. Two new roles of Business & Project Manager and a business-oriented, junior Financial...
28 March 2024 14:52Ziccum-presentation och VD-intervju från Kapitalmarknadsdag nu tillgängligaNewsCorporate InformationOther Corporate InformationEnglishIR
Tisdagen den 12 mars medverkade Ziccum på Stockholm Corporate Finance’s 16:e Life Science Kapitalmarknadsdag i Stockholm. Ziccums VD, Ann Gidner, presenterade bolagets unika teknologi som öppnar upp för helt nya biologiska läkemedel...
14 March 2024 17:25Ziccum inhalable mRNA/LNP project confirms excellent properties obtained by LaminarPaceNewsCorporate InformationOther Corporate InformationEnglishIR
Ziccum has generated very good findings in the first stages of its collaborative project to engineer inhalable mRNA/LNP together with the University of Copenhagen. The results demonstrate that LaminarPace successfully produces inhalable particles with...
1 March 2024 11:12Ziccum reports significant progress in 3D-modelling project with model completionNewsCorporate InformationOther Corporate InformationEnglishIR
Ziccum AB and project partner Zurich institute of Applied Sciences (ZHAW) have made a milestone review of the LaminarPace simulation (LaPaSim) project progress and findings. The complex, dynamic model digitally replicating the LaminarPace operation has...
26 February 2024 16:00Ziccum meddelar sista dag för handel med BTUNewsCorporate ActionSharesIssuanceSwedishRegulatoryListing RegulationIR
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...
26 February 2024 16:00Ziccum announces last day of trading in BTUNewsCorporate ActionSharesIssuanceEnglishRegulatoryListing RegulationIR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...
16 February 2024 14:30Ziccum offentliggör utfall i företrädesemissionNewsCorporate ActionSharesIssuanceSwedishRegulatoryListing RegulationIR
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...
16 February 2024 14:30Ziccum announces outcome in rights issueNewsCorporate ActionSharesIssuanceEnglishRegulatoryListing RegulationIR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...
12 February 2024 10:45Ziccums VD Ann Gidner i paneldiskussion om mRNA arrangerat av amerikanska Force Family OfficeNewsCorporate InformationOther Corporate InformationSwedishIR
Tack vare etableringen av Ziccum som en nyckelspelare för mRNA i internationell läkemedelsindustri, har Ziccums VD Ann Gidner deltagit i en inspelad paneldebatt, s.k. Fireside chat, med diskussion och inblickar i mRNA-fältet, dess rekordsnabba...
12 February 2024 10:45Ziccums CEO Ann Gidner in Fireside Chat on mRNA development hosted by US Force Family OfficeNewsCorporate InformationOther Corporate InformationEnglishIR
Based on the growing reputation that Ziccum is building in the international pharmaceutical industry, Ziccum CEO Ann Gidner has taken part in a recorded Fireside Chat reviewing the mRNA arena, its tremendous growth, and the shortcomings of the RNA/LNP...
9 February 2024 09:00Sista dag för handel med uniträtter i ZiccumNewsCorporate InformationOther Corporate InformationSwedishRegulatoryListing RegulationIR
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...
9 February 2024 09:00Last day for trading in unit rights in ZiccumNewsCorporate InformationOther Corporate InformationEnglishRegulatoryListing RegulationIR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...
8 February 2024 10:37Ziccums Styrelse och Ledningsgrupp nyttjar samtliga sina Uniträtter i den pågående nyemissionen.NewsCorporate ActionSharesIssuanceSwedishIR
Den 22e januari meddelade Ziccum att finansiering till 2025 säkrats genom en kombinerad riktad emission och företrädesemission. Teckningskursen per Unit i Företrädesemissionen uppgår till 6,80 SEK och varje Unit består...
8 February 2024 10:37Ziccum's Board of Directors and Management Group use all their Unit Rights in the ongoing new share issue.NewsCorporate ActionSharesIssuanceEnglishIR
On January 22, Ziccum announced that financing until 2025 had been secured through a combined directed issue and rights issue. The subscription price per Unit in the Rights Issue amounts to SEK 6.80 and each Unit consists of one (1) share and one (1)...
5 February 2024 10:50Ziccum CEO videointervju: mRNA i fokusNewsCorporate InformationOther Corporate InformationSwedishIR
I en intervju på svenska med Ziccums vd Ann Gidner, diskuteras företagets nya in vivo mRNA-data in-vivo, mRNA-teknologin och dess marknadspotential, samt hur Ziccums teknologi kan lösa viktiga stabilitets- och leveransutmaningar som finns...
5 February 2024 10:50Ziccum CEO video interview: mRNA in focusNewsCorporate InformationOther Corporate InformationEnglishIR
In an interview in Swedish, Ziccum CEO Ann Gidner discusses the company's new in vivo mRNA data, the mRNA market potential and technology and how Ziccum's LaminarPace can solve crucial stability and delivery challenges that can help unlock the full potential...
3 February 2024 12:20Välkommen till 'Invest Live' för att se Ziccums VD Ann Gidner presentera bolaget, som hålls live med efterföljande frågestund, tisdag den 6 februariNewsCorporate InformationOther Corporate InformationSwedishIR
Ziccums VD, Ann Gidner, presenterar bolagets unika torkningsteknologi för biologiska läkemedel samt bolagets nyligen publicerade och banbrytande mRNA-data. Detta live-evenemang hålls digitalt med Investor Target. Deltagare kan ställa...
Next